The global Connected Drug Delivery Devices Market size was estimated at USD 330 Million in 2021, and is expected to reach USD 1.6 Billion by 2028, expanding at a stellar CAGR of 23.6%.
| Attribute | Details |
|---|---|
| Connected Drug Delivery Devices Market Size (2022) | USD 448 Million |
| Sales Forecast (2028) | USD 1.6 Billion |
| Projected Market Growth Forecast (2022 to 2028) | 23.6% CAGR |
| Regional Market With Highest Share | North America - 51.5% |
Sales of connected drug delivery devices contribute 3.7% share to the global novel drug delivery system market. Drug delivery in nanotechnology has been extensively researched on, and this is expected to spawn new innovative drug delivery methods going ahead.
Explore FMI!
Book a free demo
| Particulars | Details |
|---|---|
| H1, 2021 | 25.73% |
| H1, 2022 Projected | 23.59% |
| H1, 2022 Outlook | 22.79% |
| BPS Change - H1, 2022 (O) - H1, 2022 (P) | (-) 80 ↓ |
| BPS Change - H1, 2022 (O) - H1, 2021 | (-) 294 ↓ |
With the influence of various macroeconomic, industrial and regulatory variables, the comparative analysis of market growth rate of global connected drug delivery devices market has been studied by Future Market Insights.
As per the study, the global market will show a negative BPS growth in H1-2022 outlook as compared to H1-2022 projected period by 80 BPS, and, a decline in BPS growth is expected in H1-2022 over H1- 2021 duration with 294 Basis Point Share (BPS).
Key barriers to the broader adoption of connected devices include data privacy laws that may prevent data sharing with HCPs in some countries, as well as the need to demonstrate that the tools are consistently used and generate a high-quality and reproducible database. These factors impose a negative impact as observed in the BPS value change.
However, there are some positive factors that will help push the market growth in the upcoming years which includes growing development of connected drug delivery systems with features like adherence trackers, patient education tools, dose reminders, patient diaries to gather patient-reported outcomes, and monitoring systems with interfaces between patients and healthcare professionals (HCPs).
This will enable patient monitoring and counselling in a home setting, thereby providing lucrative growth opportunities for the market players.
The healthcare industry has seen major changes over the past years, and most of these were driven by increased technological proliferation in the industry.
Drug delivery has become one of the most researched areas in the healthcare industry, and since patient engagement has become essential in the medical sector, demand for connected drug delivery devices has also risen significantly.
Injectable drug delivery devices are expected to be most popular over the next few years as they have multiple functionalities and can be used for drug tracking, drug delivery, as well as drug identification.
Rising preference for these among the population is expected to boost sales of injectable drug delivery devices over the forecast period.
Rising penetration of IoT (Internet of Things) in the medical industry, advances in drug delivery nanotechnology, innovative product launches, increasing awareness about connected drug therapy, and rising trend of home care are some of the major factors that are positively influencing the sales of connected drug delivery devices across the globe.
Demand for connected drug delivery devices increased at a phenomenal CAGR of 26.3% from 2015 to 2021, and is slated to continue surging at 23.6% CAGR from 2022 to 2028,
This research details the global connected drug delivery devices industry across North America, Latin America, Europe, East Asia, South Asia & Pacific, and the Middle East & Africa (MEA).
The North America connected drug delivery devices market, which is set to hold a significant market share of 51.5% in 2022, is expected to maintain this dominance over the forecast period as well.
Increasing healthcare expenditure and rising awareness are majorly propelling the sales of connected drug delivery devices in the region.
The market for connected drug delivery devices in Europe holds the second-highest market share of over 28%. Demand for connected drug delivery products in Europe is expected to rise at the fastest CAGR among all regions. Rapid growth can be attributed to increasing prevalence of chronic diseases in the region.
Market growth of connected drug delivery devices in East Asia, South Asia, and the Pacific is expected to see limited due to major factors influencing the sales and adoption of connected drug delivery devices. Majorly, high cost of connected drug delivery devices is restraining the market potential in these regions.
Connected drug delivery system manufacturers can target these regions to gain from the untapped market potential with competitive pricing and affordable products.
The connected drug delivery devices market in the MEA region, which merely contributes 1.9% to the global market share, is expected to rise at a sluggish CAGR. This is majorly due to high costs and little to no awareness about connected drug delivery devices.
However, as the region develops, it would offer some good opportunities for manufacturers and distributors of connected drug delivery devices to boost their sales.
The healthcare industry in the USA has been experiencing great growth over the past few years, and is expected to continue to do so over the forecast period as well. The nation has seen substantial increase in the adoption of connected drug delivery equipment.
Factors such as high per capita healthcare spending, rising adoption of new medical technologies, and increasing awareness about the adverse effects of non-compliance with drug therapy are majorly driving the sales of connected drug delivery products in the USA
The Japanese connected drug delivery devices market in 2022 is slated to hold 5.1% share of the global market. The nation is always regarded as one of the most technologically advanced in the world, and it only befits that Japan is leading the adoption of healthcare and medical technologies than most nations.
Japan has very high technological proliferation in the healthcare sector, and this makes it a very lucrative market for connected drug delivery device suppliers.Demand for connected drug delivery equipment is also expected to be boosted by the rising geriatric population in Japan, which is also fuelling demand for home care solutions in the nation.
Sales of connected drug delivery systems are expected to see a rise over the forecast period as the popularity and effectiveness of these devices rise.
Connected drug delivery devices work majorly on two technologies - Bluetooth and near field communication (NFC). Bluetooth technology connected drug delivery devices contribute more than 3/5 of the global revenue of the industry.
This segment is expected to further grow as advancements in Bluetooth technology pace over the coming years. Low cost of implementation and easy availability make Bluetooth the first choice for many connected drug delivery device manufacturers.
However, NFC technology connected drug delivery devices are expected to rise at the fastest CAGR as these devices are becoming popular for drug identification and tracking purposes, along with having more flexibility and versatility than Bluetooth-operated devices.
| Attribute | Details |
|---|---|
| Forecast Period | 2022 to 2028 |
| Historical Data Available for | 2015 to 2021 |
| Market Analysis | USD Million for Value, Units for Volume |
| Key Regions Covered | North America; Latin America; Europe; East Asia; South Asia & Pacific; Middle East & Africa (MEA) |
| Key Countries Covered | United States, Canada, Brazil, Mexico, Germany, UK, France, Spain, Italy, China, Japan, South Korea, India, Indonesia, Malaysia, Singapore, Australia, New Zealand, Turkey, South Africa, and GCC Countries |
| Key Market Segments Covered | Product Type, End User, Application, Technology, Region |
| Key Companies Profiled | Bayer AG.; Propeller Health; West Pharmaceutical Services Inc.; 3M Company; OPKO Health; Sagentia (Science Group); Care TRx; CeQur SA; Biocorp Production SA |
| Pricing | Available upon Request |
The connected drug delivery devices market is projected to grow at a remarkable CAGR of 23.6%, reaching a market value of USD 1.6 billion by 2028.
The region with the maximum uptake of connected drug delivery devices is North America, primarily centered in the United States.
As the popularity of these devices increases, connected drug delivery systems are expected to experience a rise in sales in Japan through 2028.
A significant barrier confronted by manufacturers is the imperative to seamlessly integrate with established healthcare systems.
Factors driving the market growth include the rising prevalence of chronic diseases, demand for personalized healthcare, and improved medication adherence.
The competitive landscape features a mix of established players and emerging companies. Some prominent players include Bayer AG, Propeller Health, West Pharmaceutical Services Inc., and 3M Company, among others.
Acrylic Teeth Market Trends and Assessment for 2025 to 2035
Bariatric Beds Market Analysis and Forecast for 2025 to 2035
Atypical Hemolytic Uremic Syndrome (aHUS) Treatment Market Growth and Analysis: 2025 to 2035
Retinal Vein Occlusion Treatment Market - Outlook 2025 to 2035
Klinefelter Syndrome Therapeutics Market - Growth & Demand 2025 to 2035
Veterinary Disinfectant for Pets and Farms Market - Outlook 2025 to 2035
Connected Drug Delivery Devices Market
Thank you!
You will receive an email from our Business Development Manager. Please be sure to check your SPAM/JUNK folder too.
